Connect with us

Politics

New Mexico Officials Move To Ease Medical Psilocybin Rules Following Pushback

Published

on

“New Mexico is modeling how government, health experts, and community stakeholders can build something together.”

By Jack Gorsline, Psychedelic State(s) of America

Following significant pushback from grassroots psychedelic advocates and state lawmakers alike, the New Mexico Department of Health has announced plans to strip two controversial provisions from its proposed medical psilocybin rules: a mandatory in-person checkup with an independent certifying clinician and a requirement for landlord approval at treatment sites.

Detailed in a November 9 response to public feedback on a draft rule, these updates represent proposed amendments rather than finalized regulations.

The state’s shift comes in response to what officials described as a “substantial volume of comments,” which raised concerns that the initial draft would burden rural residents, military veterans, patients at the end of life and individuals living in federally assisted housing.

Laid out in a 10-page letter from Deputy General Counsel Christopher D. Woodward to rulemaking Hearing Officer Craig Erickson of Utton & Kery, P.A., the proposal also shortens patient enrollment timelines, relaxes group session staffing requirements and clarifies that microdosing is not prohibited in approved settings. The department also says it does not intend to charge a fee for permits, certificates, or applications.

Under the original text, patients were required to undergo an in-person examination within the previous six months, conducted by a separate certifying clinician holding a New Mexico controlled-substance registration.

Commenters argued that this requirement burdened rural patients, raised costs and failed to accommodate patients at the end of life, and that it would create greater obstacles for veterans treated within the Department of Veterans Affairs system, whose providers, as federal employees, are prohibited from certifying patients for psilocybin, a Schedule I drug under federal law.

To address these concerns, health officials plan to eliminate the separate certifying clinician role, the six-month in-person exam requirement and the controlled-substance registration requirement altogether.

Instead, treating practitioners will manage entry into the program by handling patient screening, referrals, and certifications directly.

Although the Medical Psilocybin Act defines a qualified patient as one whose clinician has judged them a medically appropriate candidate, the department noted that practitioners are a type of clinician certified by the department, so practitioner certification meets that statutory requirement.

Under the updated section, practitioners must attest that they completed a required department screening tool. They must refer the patient to a medical provider if the screening indicates medical risks, if the patient hasn’t seen a medical provider in the previous 12 months or at the practitioner’s own discretion.

The rule will list contraindicated conditions and treatments including cardiovascular disease, seizure disorder or history of seizure, moderate or greater head trauma, hypertension, history of stroke or cerebrovascular disease, asthma or COPD, diabetes, psychosis or disease with a risk of psychosis (including bipolar disorder), medication interactions such as lithium and serotonergic drugs, a history of suicide attempt or thoughts of harming oneself or others and the use of medical devices such as insulin pumps and pacemakers.

Practitioners must also attest that the benefits of psilocybin likely outweigh its health risks for the patient, and that any identified medical risks can be adequately addressed during treatment or are covered by a written plan.

“This will effectively remove the requirement that every examination be in-person. This screening process will be more individual-specific and should be less burdensome for patients in the program,” Woodward wrote.

Legal advocates noted that New Mexico’s willingness to adjust its rules stands in stark contrast to the regulatory rollout in Oregon, where rigid restrictions on treatment locations have sparked federal disability litigation.

“It is great to see the responsiveness of the NM Dept. of Health in the rulemaking process in NM; this contrasts sharply with how Oregon failed to respond to public comment in its rulemaking,” said Kathryn Tucker, director of advocacy for the National Psychedelics Association.

“For example, despite being alerted to how the Service Center restriction in Oregon’s law would operate as an insurmountable barrier to access for homebound disabled and dying Oregonians, the OHA proceeded to adopt rules baking this discrimination into the program.,” she said. “This has required facilitators with special interest and expertise in serving such consumers to resort to the federal court for relief. Argument was heard yesterday in this matter, Cusker v. OHA, where the court seemed (properly) concerned with the apparent violation of the ADA, a landmark civil liberties statute guaranteeing that no State or local government can operate a program without ensuring access for disabled persons. We hope for a clear ruling from the court soon.”

The agency also intends to strike provisions that would have required healing centers and other approved locations to obtain a statement from the landlord or property owner.

Under the new draft, applicants need only attest that they own the property or that they are aware of the legal risk concerning the property. Patients, in turn, must attest that they have been informed of psilocybin’s legal status as a federal Schedule I drug and the potential consequences of using it, which the department noted may, in some circumstances, include forfeiture of property.

“In adopting these provisions, the Department seeks to ensure that applicants for healing centers and other approved locations, and patients, are enabled to make informed decisions,” Woodward stated in the November 9 letter.

Department officials noted that dropping the landlord consent requirement means public concerns regarding potential conflicts with Section 8 and other federally assisted housing programs “are effectively resolved”.

To streamline access, the department proposes cutting the maximum processing period from 30 calendar days to 10 business days. The revision replaces references to “applicant” with “patient” and adds text clarifying that this is an enrollment process rather than a more involved application process.

“The patient enrollment process is not intended to be an involved process, and does not require the Department to render any clinical decisions regarding individual patients, or to collect detailed clinical records,” the letter notes.

Addressing affordability, a central concern since the state funded a Medical Psilocybin Treatment Equity Fund for patients on low incomes, the letter states that the department “does not intend to charge a fee for permits, certificates, or applications,” which it says should help alleviate costs for permitted and certified persons and entities.

The department added that it cannot fully assess cost and affordability until more is known about what providers will charge, and that it lacks authority to restrict or set practitioner fees.

Responding to commenters who sought a separate low-cost microdosing pathway, the department declined to create one but clarified that the existing framework already accommodates low doses. “Microdosing is not prohibited by the existing framework where the practitioner and patient agree to use low doses, provided that administration occurs in the approved settings as required by statute,” Woodward explained.

To help reduce treatment costs further, the department proposed updating group administration ratios to allow one practitioner for every nine patients, supported by at least one additional practitioner, facilitator or qualified student for every three patients, with the practitioner required only to be in the building, within range to be called in for an emergency, rather than in the session room. Individual sessions will require one practitioner plus one additional practitioner or facilitator.

However, regulators declined to allow vertical integration of cultivation and administration, citing potential conflicts of interest and arguing that it could raise statewide production costs and the department’s oversight burden.

“While the Department does not propose to adopt every edit suggested in public comments, the depth and breadth of comments received has resulted in several substantial revisions,” Woodward concluded.

“New Mexico is modeling how government, health experts, and community stakeholders can build something together,” said Denali Wilson, New Mexico director of strategic support for Healing Advocacy. “A wide variety of leaders in behavioral health, psychedelic medicine, patient and advocacy communities weighed in to help shape the draft rules into final versions that accomplish our shared goals for safety, accessibility, and quality of care. We’re grateful for the Department’s commitment to that collaborative process and we’re confident that ongoing partnership will help New Mexico build a high-quality, equitable program for the people who are counting on it.”

For veterans and grassroots organizers, the revisions validate months of sustained public pressure.

“This is what public comment is supposed to do. New Mexicans showed up, wrote in, and kept advocating month after month,” said Chris Peskuski, a Marine Corps veteran in Albuquerque, Heroic Hearts Project Ambassador and a peer facilitator on the University of New Mexico’s psilocybin study for PTSD.

“I’m proud of my fellow advocates who stayed steady and put themselves out there fighting for a safe, accessible program.”

This article was produced in partnership with Psychedelic State(s) of America—a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Subscribe to PSA online and Follow PSA on Instagram, LinkedIn, Twitter/X and  Facebook. Learn more about PSA and donate to the PSA Media Fund here. 

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Become a patron at Patreon!
Advertisement

Marijuana News In Your Inbox

Get our daily newsletter.

Support Marijuana Moment

Add Marijuana Moment as a preferred source on Google.

Marijuana News In Your Inbox

 

Get our daily newsletter.